ReviewReviews in medical virology2014
Towards nanomedicines for neuroAIDS.
Review in Reviews in medical virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Recent Nanotherapeutic Advancements Against HIV-Associated Neurocognitive Disorders (HAND).Biomolecules · 2026Review
- Nanomaterials as drug delivery agents for overcoming the blood-brain barrier: A comprehensive review.ADMET & DMPK · 2024Review
- Nano-based drug delivery system: a smart alternative towards eradication of viral sanctuaries in management of NeuroAIDS.Drug delivery and translational research · 2022Review
- Nanoparticle delivery system, highly active antiretroviral therapy, and testicular morphology: The role of stereology.Pharmacology research & perspectives · 2021Review
- Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers.Pharmaceutics · 2020Review
- Nose to brain delivery of antiretroviral drugs in the treatment of neuroAIDS.Molecular biomedicine · 2020Review
- Magnetically guided non-invasive CRISPR-Cas9/gRNA delivery across blood-brain barrier to eradicate latent HIV-1 infection.Scientific reports · 2019Article
- Alzheimer's disease: pathogenesis, diagnostics, and therapeutics.International journal of nanomedicine · 2019Review
- Enhancement of saquinavir absorption and accumulation through the formation of solid drug nanoparticles.BMC pharmacology & toxicology · 2018Article
- Aptamers in HIV research diagnosis and therapy.RNA biology · 2018Review
- Near-infrared biophotonics-based nanodrug release systems and their potential application for neuro-disorders.Expert opinion on drug delivery · 2018Review
- Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2017Review
- Common gene-network signature of different neurological disorders and their potential implications to neuroAIDS.PloS one · 2017Article
- Nano-ART and NeuroAIDS.Drug delivery and translational research · 2016Review
- Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future Prospective.Advanced pharmaceutical bulletin · 2016Review
- In Vitro Permeation of FITC-loaded Ferritins Across a Rat Blood-brain Barrier: a Model to Study the Delivery of Nanoformulated Molecules.Journal of visualized experiments : JoVE · 2016Article
- Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS.Advanced drug delivery reviews · 2016Review
- Coupling of transient near infrared photonic with magnetic nanoparticle for potential dissipation-free biomedical application in brain.Scientific reports · 2016Article
- Magnetic nanotherapeutics for dysregulated synaptic plasticity during neuroAIDS and drug abuse.Molecular brain · 2016Review
- Magnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Although highly active antiretroviral therapy (HAART) has resulted in remarkable decline in the morbidity and mortality in AIDS patients, controlling HIV infections still remain a global health priority. HIV access to the CNS serves as the natural viral preserve because most antiretroviral (ARV) drugs possess inadequate or zero delivery across the brain barriers. Thus, development of target-specific, effective, safe, and controllable drug-delivery approach is an important health priority for global elimination of AIDS progression. Emergence of nanotechnology in medicine has shown exciting prospect for development of novel drug delivery systems to administer the desired therapeutic levels of ARV drugs in the CNS. Neuron-resuscitating and/or antidependence agents may also be delivered in the brain through nanocarriers to countercheck the rate of neuronal degradation during HIV infection. Several nanovehicles such as liposomes, dendrimers, polymeric nanoparticles, micelles, and solid lipid nanoparticles have been intensively explored. Recently, magnetic nanoparticles and monocytes/macrophages have also been used as carrier to improve the delivery of nanoformulated ARV drugs across the blood-brain barrier. Nevertheless, more rigorous research homework has to be elucidated to sort out the shortcomings that affect the target specificity, delivery, release, and/or bioavailability of desired amount of drugs for treatment of neuroAIDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.